These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32969202)

  • 1. First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator.
    Ye Y; Gaudy A; Schafer P; Thomas M; Weiss D; Chen N; Liu L; Xue Y; Carayannopoulos L; Palmisano M
    Clin Pharmacol Drug Dev; 2021 May; 10(5):471-485. PubMed ID: 32969202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.
    Merrill JT; Werth VP; Furie R; van Vollenhoven R; Dörner T; Petronijevic M; Velasco J; Majdan M; Irazoque-Palazuelos F; Weiswasser M; Korish S; Ye Y; Gaudy A; Schafer PH; Liu Z; Agafonova N; Delev N
    N Engl J Med; 2022 Mar; 386(11):1034-1045. PubMed ID: 35294813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.
    Schafer PH; Ye Y; Wu L; Kosek J; Ringheim G; Yang Z; Liu L; Thomas M; Palmisano M; Chopra R
    Ann Rheum Dis; 2018 Oct; 77(10):1516-1523. PubMed ID: 29945920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study.
    Furie RA; Hough DR; Gaudy A; Ye Y; Korish S; Delev N; Weiswasser M; Zhan X; Schafer PH; Werth VP
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35169036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide.
    Liu Y; Mo CC; Hartley-Brown MA; Sperling AS; Midha S; Yee AJ; Bianchi G; Piper C; Tattersall A; Nadeem O; Laubach JP; Richardson PG
    Expert Rev Hematol; 2024 Aug; 17(8):445-465. PubMed ID: 39054911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.
    Rasco DW; Papadopoulos KP; Pourdehnad M; Gandhi AK; Hagner PR; Li Y; Wei X; Chopra R; Hege K; DiMartino J; Shih K
    Clin Cancer Res; 2019 Jan; 25(1):90-98. PubMed ID: 30201761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Dose Pharmacokinetics, Safety, and Tolerability of Avadomide (CC-122) in Subjects With Mild, Moderate, or Severe Renal Impairment.
    Li Y; MacGorman K; Liu L; Chen J; Hoffmann M; Palmisano M; Zhou S
    Clin Pharmacol Drug Dev; 2020 Oct; 9(7):785-796. PubMed ID: 31891240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-resolution structures of the bound effectors avadomide (CC-122) and iberdomide (CC-220) highlight advantages and limitations of the MsCI4 soaking system.
    Heim C; Hartmann MD
    Acta Crystallogr D Struct Biol; 2022 Mar; 78(Pt 3):290-298. PubMed ID: 35234143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
    Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
    Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I, Open-Label, Mass Balance Study of [
    Cheng Y; Wang X; Liu L; Silva J; Thomas M; Li Y
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):355-365. PubMed ID: 38521893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological impact of iberdomide in patients with active systemic lupus erythematosus.
    Lipsky PE; Vollenhoven RV; Dörner T; Werth VP; Merrill JT; Furie R; Petronijevic M; Velasco Zamora B; Majdan M; Irazoque-Palazuelos F; Terbrueggen R; Delev N; Weiswasser M; Korish S; Stern M; Hersey S; Ye Y; Gaudy A; Liu Z; Gagnon R; Tang S; Schafer PH
    Ann Rheum Dis; 2022 Apr; 81(8):1136-42. PubMed ID: 35477518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.
    Cheng Y; Ye Y; Gaudy A; Ghosh A; Xue Y; Wang A; Zhou S; Li Y
    Clin Pharmacol; 2023; 15():9-19. PubMed ID: 36880014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
    Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
    Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN.
    Bjorklund CC; Kang J; Amatangelo M; Polonskaia A; Katz M; Chiu H; Couto S; Wang M; Ren Y; Ortiz M; Towfic F; Flynt JE; Pierceall W; Thakurta A
    Leukemia; 2020 Apr; 34(4):1197-1201. PubMed ID: 31719682
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
    Amatangelo M; Flynt E; Stong N; Ray P; Van Oekelen O; Wang M; Ortiz M; Maciag P; Peluso T; Parekh S; van de Donk NWCJ; Lonial S; Thakurta A
    Cell Rep Med; 2024 Jun; 5(6):101571. PubMed ID: 38776914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Imarikiren, a Novel Renin Inhibitor, in Healthy Male Subjects.
    Matsuno K; Kuroda S; Tanaka S; Nakamichi H; Kagawa T; Koumura E
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):607-614. PubMed ID: 29845723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Shinde A; Goyal VK; Pandey SK; Mohammed AR; Ravula J; Jetta S; Palacharla VRC
    Clin Drug Investig; 2020 Jul; 40(7):603-615. PubMed ID: 32399853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.